Recombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical)

重组新型冠状病毒疫苗（CHO细胞）（安徽智飞龙科马）

Report date: 2023/11/01 10:57:52

Base Information

Drug NameRecombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical)
Drug Alias NameRecombinant new coronavirus vaccine (CHO cell) (Zhifei Longcom Biopharmaceutical)重组新型冠状病毒疫苗(中逸安科)COVID-2019 vaccine (Zhifei Longcom Biopharmaceutical)智克威得ZF2001
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Biological material > Viral vaccine +[4] 
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryUzbekistan
Original Approved Date2021/03/01
Country/TerritoryUzbekistanPakistanEcuador +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAnhui Zhifei Longcom Biopharmaceutical Co LtdInstitute Of Microbiology Of Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Zhifei Longcom Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ07B
Related LinksN/A